Alnylam Pharmaceuticals
ALNY
#654
Rank
$29.91 B
Marketcap
$236.48
Share price
0.93%
Change (1 day)
22.96%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/E ratio for Alnylam Pharmaceuticals (ALNY)

P/E ratio as of July 2024 (TTM): -57.5

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -57.5377. At the end of 2022 the company had a P/E ratio of -25.6.

P/E ratio history for Alnylam Pharmaceuticals from 2004 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-25.68.61%
2021-23.635.01%
2020-17.423.3%
2019-14.146.71%
2018-9.64-58.93%
2017-23.5200.45%
2016-7.82-71.36%
2015-27.344.59%
2014-18.9-58.03%
2013-45.0412.48%
2012-8.7746.41%
2011-5.99-36.79%
2010-9.48-38.66%
2009-15.5-60%
2008-38.6191%
2007-13.3-31.75%
2006-19.5186.27%
2005-6.80909.23%
2004-0.6734

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-17.0-70.44%๐Ÿ‡บ๐Ÿ‡ธ USA
28.4-149.35%๐Ÿ‡บ๐Ÿ‡ธ USA
-18.6-67.59%๐Ÿ‡บ๐Ÿ‡ธ USA
-5.26-90.86%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.04-98.20%๐Ÿ‡บ๐Ÿ‡ธ USA
29.2-150.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
16.1-127.98%๐Ÿ‡ซ๐Ÿ‡ท France
-8.25-85.66%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.